1998. Diplôme d’Etudes Spécialisées (DES) de Pharmacie Spécialisée, Université de Pharmacie, Université de Bourgogne, Dijon
1998. Thesis in Pharmacy, UFR de Pharmacie, Université de Bourgogne, Dijon
1995. Master M2 in Biochemistry, Cellular and Molecular Biology, Mention Bien (1/32), Université des Sciences, Université de Bourgogne, Dijon
1993. Diplôme d’Etat de Pharmacie, UFR de Pharmacie, Université Joseph Fourier, Grenoble
PROFESSIONAL ACTIVITIES
Actual position: CR1 INSERM. Principal investigator (PI) inside the team 2 « Molecular Basis of Lung Cancer Progression » of INSERM unit U823. Institut Albert Bonniot. Grenoble. France.
2006- Permanent position at INSERM (Chargée de Recherche CR1).
INSERM Unit U823, Team: Molecular Basis of Lung Cancer Progression,
Institut Albert Bonniot, Grenoble, France.
«Deregulation of p53/Rb signaling pathways in human lung carcinogenesis».
2001-2005. Permanent position at INSERM (Chargée de Recherche CR2).
INSERM Unit U578, Groupe de Recherche sur le Cancer du Poumon, Institut Albert Bonniot.
1998-2001. Post-doctoral position (Poste Accueil INSERM).
INSERM Unit U578, Groupe de Recherche sur le Cancer du Poumon, Institut Albert Bonniot.
1993-1998. Interne en Pharmacie Spécialisée. CHU de Dijon
1993-1996: Hematology - Dr GUY
1996-1997: Pharmacy - Dr DURNET
1997-1998: Clinical Hematology - Dr GUY
1995-1998. Doctoral position.
INSERM Unit U517. «Cell Death and Cancer». Pr Eric Solary. Facultés de Médecine et de Pharmacie, Université de Bourgogne, Dijon.
Title of the thesis : Relationships between cell cycle and chemotherapy-induced apoptosis in human leukemic cells. Implication of gadd153 and p27Kip1.
EXPERTISE DOMAINS
Lung cancer
pre mRNA alternative splicing
Angiogenesis
Cellular proliferation and Apoptosis
Transcription factors and SR proteins
Cellular signaling pathways
TEACHING RESPONSABILITIES
Courses (4 hours) in Cellular Signaling Pathways (UE5331, Master M2 Integrative and Cellular Biology, University of Biology, Grenoble)
Jury of Master M2 « Integrative and Cellular Biology » 2007 and 2008
Member of jury of PhD
Supervisor of 4 PhD students
Supervisor of 3 Master M2 students
MEMBERSHIP OF SCIENTIFIC CONCILS
Member of the Specialist Commission of the department of Cellular Biology of the university of Biology of Grenoble (October 2007-2009)
Expert of Ligue Nationale Contre le Cancer (Comité Régional)
Lung cancer is a major public health problem. Despite diagnosis and treatment improvements, ten-years overall lung cancer survival is less than 5%, claiming more deaths than colon, breast and prostate carcinoma all togethers. Twenty-five percents of patients only can benefit of an early diagnosis allowing surgical resection, with 60-80% survival at five years. In this setting, our main objectives are to identify some of the molecular biomarkers that could be predictive of tumor progression and response to therapies. Identification of such biomarkers should improve early detection of lung tumors, as well as should help in the establishment of new targeted therapies more efficient and less agressive.
In this setting, our research focused on different aspects:
- Identification of cellular signalling pathways involved in the control of lung tumor cells proliferation and/or apoptosis.
- Identification of target genes involved in lung tumor cell response to chemotherapeutic agents and targeted therapies such as anti-angiogenic therapies.